Showing results (121-130 of 141) with videos related to

Sort By:
Pageof 15
Cancer Medicine|February 18, 2026
Durable Disease Control With Atezolizumab Plus Bevacizumab but Limited Post-Progression Outcomes: A Multicenter Real-World Study in Advanced Hepatocellular CarcinomaMasanori Inoue, Sadahisa Ogasawara, Kazuhisa Asahara, et al.
JHEP Reports : Innovation in Hepatology|December 9, 2025
The efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in relation to tumor-infiltrating lymphocytesHiroaki Kanzaki, Takamasa Ishino, Sadahisa Ogasawara, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|February 8, 2021
Propofol <i>versus</i> midazolam for sedation during radiofrequency ablation in patients with hepatocellular carcinomaNaoya Kanogawa, Sadahisa Ogasawara, Yoshihiko Ooka, et al.
BMC Gastroenterology|March 11, 2023
Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinomaNaoya Kanogawa, Sadahisa Ogasawara, Susumu Maruta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 5, 2023
A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH StudyKazufumi Kobayashi, Sadahisa Ogasawara, Susumu Maruta, et al.
Investigational New Drugs|June 8, 2019
Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in JapanSadahisa Ogasawara, Yoshihiko Ooka, Norio Itokawa, et al.
BMJ Open|June 2, 2026
Phase Ib/II trial to evaluate the safety and efficacy of atezolizumab and bevacizumab as adjuvant therapy following carbon-ion radiotherapy in hepatocellular carcinoma (VANGUARD): study protocolKeisuke Koroki, Masaru Wakatsuki, Sadahisa Ogasawara, et al.
Investigational New Drugs|June 6, 2024
Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study)Kazufumi Kobayashi, Sadahisa Ogasawara, Ei Itobayashi, et al.
Biochemical and Biophysical Research Communications|December 31, 2022
Miglustat, a glucosylceramide synthase inhibitor, mitigates liver fibrosis through TGF-β/Smad pathway suppression in hepatic stellate cellsTerunao Iwanaga, Tetsuhiro Chiba, Masato Nakamura, et al.
Liver Cancer|February 28, 2022
Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular CarcinomaKazufumi Kobayashi, Sadahisa Ogasawara, Aya Takahashi, et al.
Pageof 15